Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Annual Meeting

AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100 at ASCO 2024


AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held May 31-June 4, at McCormick Place Convention Center in Chicago, IL.

"We look forward to presenting our preliminary data at ASCO, and to provide initial safety and efficacy results from our Phase 1 trial evaluating AIC100 CAR T therapy in patients with advanced thyroid cancers," said Matt Britz, CEO, AffyImmune. "These results mark significant progress, as we continue to advance our affinity-tuned CAR T therapies for patients with unmet medical need."

Presentation Details:

Title: Safety and Efficacy of AIC100 Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Advanced Thyroid Cancers: results from the phase 1 study

Presenter: Dr. Samer Ali Srour, University of Texas MD Anderson Cancer Center

Session Type: Poster Session? Head and Neck Cancer

Abstract Number: 6112

Date and Time: June 2, 2024: 9:00 AM - 12:00 PM CDT

Location: McCormick Place Convention Center in Chicago, Illinois

About AffyImmune Therapeutics

AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies to transform the lives of patients with cancer. The Company's proprietary technology utilizing ICAM-1/LFA-1 interaction can potentially address all critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR T cells. Its lead candidate, AIC100, is an ICAM-1-directed CAR T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit www.affyimmune.com.


These press releases may also interest you

at 03:05
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global...

at 03:05
Lantern Pharma Inc. , a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of...

at 03:00
Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light....

at 03:00
A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the...

at 02:11
Calliditas Therapeutics AB ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and...

at 00:01
The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and...



News published on and distributed by: